5 completed, 1 terminated. 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Xydalba: new trials by email Literature Review of Xydalba trials Research Report on Xydalba
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) Dalbavancin - Diabetes, Infection | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 98 | 2022-01-02 | 2022-09-21 | |
| Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI Xydalba, vancomycin, teicoplanin or daptomycin - Acute Bacterial Skin and Skin Structure Infection | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 184 | 2020-06-18 | 2022-03-04 | |
| Xydalba Utilization Registry in Germany Xydalba - Bacterial Infections | Terminated | Correvio International Sarl | 16 | 2018-11-21 | 2020-07-17 | |
| Xydalba Utilization Registry in France Xydalba - Bacterial Infections | Completed | Correvio International Sarl | 151 | 2018-09-06 | 2021-07-20 | |
| Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Dalbavancin, Vancomycin - Bone Infection, Osteomyelitis | Phase 4 | Completed | Infectious Diseases Physicians, Inc. | 41 | 2018-01-25 | 2023-10-03 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
Bacterial Infections (3) · Arthritis, Infectious (1) · Cellulitis (1) · Diabetes Mellitus (1) · Infections (1) · Osteomyelitis (1) · Staphylococcal Skin Infections (1)
Aziende Chimiche Riunite Angelini Francesco S.p.A (2) · Correvio International Sarl (2) · AbbVie (1) · Infectious Diseases Physicians, Inc. (1)
Greece (2) · Italy (2) · Spain (2) · United States (2) · Argentina (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · France (1) · Georgia (1) · Germany (1) · Guatemala (1) · Latvia (1)
Donald Poretz, MD (1) · Kiran Bhirangi, MBBS FRCS I (1)
2014 (1)